Back to search results

Cardiac Radioablation for Ventricular Tachycardia

This study is testing a treatment called Stereotactic Body Radiation Therapy (SBRT), a precise, high-dose radiation treatment, for people with Ventricular Tachycardia (VT) that hasn't improved with other treatments. The goal is to find the lowest effective dose of SBRT to reduce VT episodes. You might be able to join if you are 18 or older, have an automatic implanted cardiac defibrillator, have had VT despite medications and at least one previous heart ablation, and your heart's pumping ability (ejection fraction) is at least 20%. The study will measure how much the number of VT episodes changes after SBRT and will also look for any serious side effects. This study is currently not recruiting.

Study design
This is an interventional study planning to enroll 24 participants. It aims to find the minimum effective dose of radiation therapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure changes in VT episodes for 98 days after treatment, and dose-limiting toxicities for 14 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06593418

Cardiac Radioablation for VT

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Corewell Health East
~24 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:Stereotactic Body Radiation Therapy (SBRT)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in number of ventricular tachycardia (VT) episodes from pre-cardiac radioablation to post-cardiac radioablation
Measured over 56 days pre-treatment and 98 days post treatment (42 day blanking period plus 56 days)
+1 more outcome measured

Conditions

Ventricular Tachycardia
Myocardial Infarction

Explore related trials

Myocardial InfarctionVentricular Tachycardia

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • John Robertson, MD · PRINCIPAL_INVESTIGATOR · Corewell Health William Beaumont University Hospital

Who to contact

John Roberston, MD
[email protected]
248-551-7038
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must be 18 years or older.
Automatic implanted cardiac defibrillator present.
VT is monomorphic with at least two episodes of VT within an eight week (56 day) period as recorded by an AICD or heart failure related to VT or VT storm.
Ejection fraction ≥20%.
At least one previous cardiac ablation for VT.
VT refractory despite antiarrhythmic medications.
Likely to live for 12 months in the absence of VT.
AICD in a position in the chest RT to be given without direct radiation.
Woman of reproductive age must ensure that she won't become pregnant or breastfeed at the time of RT.
The participant has no contraindications to a Cardiac MRI as per routine Cardiology practice.

Exclusion

Class IV heart failure
Abandoned leads.
Prior radiation therapy to the chest or upper abdomen.
Interstitial lung disease.

What this trial measures

  • Change in number of ventricular tachycardia (VT) episodes from pre-cardiac radioablation to post-cardiac radioablation56 days pre-treatment and 98 days post treatment (42 day blanking period plus 56 days)

    Change in the number of episodes of VT over the 56 days before treatment versus over a consecutive 56 days post treatment (following the 6 week post-treatment blanking period). A negative number represents a reduction in episodes after treatment (improved function) and a positive number represents an increase in episodes after treatment (worsened function).

  • Dose limiting toxicity14 weeks

    Number of participants who had dose limiting toxicity defined as any grade 3 toxicity requiring hospitalization or any grade 4-5 toxicity determined to be treatment-related.